Weibo Zhong

589 citations
12 papers · 362 indexed · 1 hit paper · h-index 7
Topics
Circular RNAs in diseases (5 papers)Cancer-related molecular mechanisms research (5 papers)MicroRNA in disease regulation (5 papers)

In The Last Decade

Weibo Zhong

11 papers receiving 362 citations

Hit Papers

Gut dysbiosis promotes prostate cancer progression and do...202220262023202420224080120

Peers

Weibo Zhong
Comparison fields: 5 of 63
  • Molecular Biology 246
  • Cancer Research 157
  • Pulmonary and Respiratory Medicine 85
  • Oncology 71
  • Epidemiology 26
Replace Chuanfan Zhong with:
Chuanfan Zhong China
Yuki Oda Japan
Facai Zhang China
Hu Qiu China
Hengcun Li China
Pei He China
Wang Li China
Xufeng Huang Hungary
Peipei Xu China
Jun Meng China
Weibo Zhong relative to Chuanfan Zhong China Chuanfan Zhong's profile →
Citations per field
00.5×1.5×
Chuanfan Zhong · 1×
Citations per year

Countries citing papers authored by Weibo Zhong

Since Specialization
Citations

This map shows the geographic impact of Weibo Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weibo Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weibo Zhong more than expected).

Fields of papers citing papers by Weibo Zhong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weibo Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weibo Zhong. The network helps show where Weibo Zhong may publish in the future.

Co-authorship network of co-authors of Weibo Zhong

This figure shows the co-authorship network connecting the top 25 collaborators of Weibo Zhong. A scholar is included among the top collaborators of Weibo Zhong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weibo Zhong. Weibo Zhong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
#WorkIndexed citations
1 4
2 1
3 2
4 3
5 0
6 39
7
Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axisbreakdown →
132
8 15
9 27
10 22
11 33
12 84

About Weibo Zhong

Weibo Zhong is a scholar working on Cancer Research, Clinical Biochemistry and Nephrology, having authored 12 papers that have together received 362 indexed citations. Recurring topics across this work include Circular RNAs in diseases (5 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (5 papers). The work is most often cited by research in Cancer Research (157 citations), Molecular Biology (246 citations) and Oncology (71 citations). Weibo Zhong has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Jianming Lü, Chuanfan Zhong, Xiangming Mao, Kaihui Wu, Zining Long, Taowei Yang, Yufei Guo, Daojun Lv, Xumin Zhou and Shuo Wang. Their work appears in journals such as Frontiers in Immunology, Medicine and Cell Death and Disease.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026